Gallium modulates osteoclastic bone resorption in vitro without affecting osteoblasts

British Journal of Pharmacology

Volumn 159, Issue 8, 2010, Pages 1681-1692

  Verron, Elise ^a,b,c   Masson, Martial ^a,b   Khoshniat, Solmaz ^a,b   Duplomb, Laurence ^b,d   Wittrant, Yohann ^a,b   Baud'Huin, Marc ^b,d   Badran, Zahi ^a,e   Bujoli, Bruno ^b,f   Janvier, Pascal ^b,f   Scimeca, Jean Claude ^g   Bouler, Jean Michel ^a,b   Guicheux, Jérôme ^a,b  

^a Universite de Nantes   (France)

^b Nantes Atlantic University   (France)

^c Graftys SARL   (France)

^d INSERM   (France)

^e ERT 1004   (France)

^f Centre National de la Recherche Scientifique   (France)

^g CNRS   (France)

Author keywords

Bone resorption; Gallium; Osteoblast; Osteoclast; Osteoporosis

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; GALLIUM; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFATC1; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL ACTIVITY; CELL DIFFERENTIATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; ERYTHROCYTE; HUMAN; HUMAN CELL; IN VITRO STUDY; LONG BONE; MOUSE; MULTINUCLEAR CELL; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ACID PHOSPHATASE; ALKALINE PHOSPHATASE; ANIMALS; BASE SEQUENCE; BONE RESORPTION; CELL DIFFERENTIATION; CELLS, CULTURED; DNA PRIMERS; GALLIUM; HUMANS; ISOENZYMES; MICE; OSTEOBLASTS; RABBITS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77950235381     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00665.x     Document Type: Article

References (49)

1. Asagiri M, Takayanagi H (2007). The molecular understanding of osteoclast differentiation. Bone 40 : 251 264.
2. van Balen R, Steyerberg EW, Polder JJ, Ribbers TL, Habbema JD, Cools HJ (2001). Hip fracture in elderly patients: outcomes for function, quality of life, and type of residence. Clin Orthop Relat Res 390 : 232 243.
3. Benezeth P, Diakonov II, Pokrovski GS, Dandurand JL, Schott J, Khodakovsky IL (1997). Gallium speciation in aqueous solution. Experimental study and modelling.2. Solubility of alpha-GaOOH in acidic solutions from 150 to 250 degrees C and hydrolysis constants of gallium (III) to 300 degrees C. Geochimica Et Cosmochimica Acta 61 : 1345 1357.
4. Blair HC (1998). How the osteoclast degrades bone. Bioessays 20 : 837 846.
5. Blair HC, Teitelbaum SL, Tan HL, Schlesinger PH (1992). Reversible inhibition of osteoclastic activity by bone-bound gallium (III). J Cell Biochem 48 : 401 410.
6. Bockman RS, Guidon PT, Jr., Pan LC, Salvatori R, Kawaguchi A (1993). Gallium nitrate increases type I collagen and fibronectin mRNA and collagen protein levels in bone and fibroblast cells. J Cell Biochem 52 : 396 403.
7. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP et al. (2004). Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350 : 1189 1199.
8. Consensus Development Conference (1993). Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94 : 646 650.
9. Cramer JA, Gold DT, Silverman SL, Lewiecki EM (2007). A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18 : 1023 1031.
10. Donnelly R, Bockman RS, Doty SB, Boskey AL (1991). Bone particles from gallium-treated rats are resistant to resorption in vivo. Bone Miner 12 : 167 179.
11. Duplomb L, Baud'huin M, Charrier C, Berreur M, Trichet V, Blanchard F et al. (2008). Interleukin-6 inhibits receptor activator of nuclear factor kappaB ligand-induced osteoclastogenesis by diverting cells into the macrophage lineage: key role of Serine727 phosphorylation of signal transducer and activator of transcription 3. Endocrinology 149 : 3688 3697.
12. Emkey RD, Ettinger M (2006). Improving compliance and persistence with bisphosphonate therapy for osteoporosis. Am J Med 119 : S18 S24.
13. Ensrud KE, Thompson DE, Cauley JA, Nevitt MC, Kado DM, Hochberg MC et al. (2000). Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. Fracture Intervention Trial Research Group. J Am Geriatr Soc 48 : 241 249.
14. Faucheux C, Verron E, Soueidan A, Josse S, Arshad MD, Janvier P et al. (2008). Controlled release of bisphosphonate from a calcium phosphate biomaterial inhibits osteoclastic resorption in vitro. J Biomed Mater Res A : 46 56.
15. Fisher JE, Rodan GA, Reszka AA (2000). In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology 141 : 4793 4796.
16. Gallagher AM, Rietbrock S, Olson M, van Staa TP (2008). Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res 23 : 1569 1575.
17. Grimandi G, Soueidan A, Anjrini AA, Badran Z, Pilet P, Daculsi G et al. (2006). Quantitative and reliable in vitro method combining scanning electron microscopy and image analysis for the screening of osteotropic modulators. Microsc Res Tech 69 : 606 612.
18. Guicheux J, Heymann D, Rousselle AV, Gouin F, Pilet P, Yamada S et al. (1998). Growth hormone stimulatory effects on osteoclastic resorption are partly mediated by insulin-like growth factor I: an in vitro study. Bone 22 : 25 31.
19. Guicheux J, Lemonnier J, Ghayor C, Suzuki A, Palmer G, Caverzasio J (2003). Activation of p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase by BMP-2 and their implication in the stimulation of osteoblastic cell differentiation. J Bone Miner Res 18 : 2060 2068.
20. Guidon PT, Jr., Salvatori R, Bockman RS (1993). Gallium nitrate regulates rat osteoblast expression of osteocalcin protein and mRNA levels. J Bone Miner Res 8 : 103 112.
21. Hall TJ, Chambers TJ (1990). Gallium inhibits bone resorption by a direct effect on osteoclasts. Bone Miner 8 : 211 216.
22. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD et al. (1995). Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10 : 1478 1487.
23. Huybrechts KF, Ishak KJ, Caro JJ (2006). Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38 : 922 928.
24. Jenis LG, Waud CE, Stein GS, Lian JB, Baran DT (1993). Effect of gallium nitrate in vitro and in normal rats. J Cell Biochem 52 : 330 336.
25. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA, 3rd., Berger M (2000). Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15 : 721 739.
26. Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB et al. (2001). Risk of new vertebral fracture in the year following a fracture. JAMA 285 : 320 323.
27. Ma Z, Fu Q (2009). Therapeutic effect of organic gallium on ovariectomized osteopenic rats by decreased serum minerals and increased bone mineral content. Biol Trace Elem Res DOI: 10.1007/s12011-009-8445-3.
28. McClung MR (2000). Bisphosphonates in osteoporosis: recent clinical experience. Expert Opin Pharmacother 1 : 225 238.
29. Magne D, Bluteau G, Faucheux C, Palmer G, Vignes-Colombeix C, Pilet P et al. (2003). Phosphate is a specific signal for ATDC5 chondrocyte maturation and apoptosis-associated mineralization: possible implication of apoptosis in the regulation of endochondral ossification. J Bone Miner Res 18 : 1430 1442.
30. Matkovic V, Apseloff G, Shepard DR, Gerber N (1990). Use of gallium to treat Paget's disease of bone: a pilot study. Lancet 335 : 72 75.
31. Melton LJ, 3rd., Chrischilles EA, Cooper C, Lane AW, Riggs BL (1992). Perspective. How many women have osteoporosis? J Bone Miner Res 7 : 1005 1010.
32. Niesvizky R (2003). Gallium nitrate in multiple myeloma: prolonged survival in a cohort of patients with advanced-stage disease. Semin Oncol 30 : 20 24.
33. Orcel P (2005). Prevention and treatment of glucocorticoid-induced osteoporosis in 2005. Joint Bone Spine 72 : 461 465.
34. Papapoulos SE, Quandt SA, Liberman UA, Hochberg MC, Thompson DE (2005). Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int 16 : 468 474.
35. Rabenda V, Mertens R, Fabri V, Vanoverloop J, Sumkay F, Vannecke C et al. (2008). Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 19 : 811 818.
36. Reszka AA, Halasy-Nagy JM, Masarachia PJ, Rodan GA (1999). Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J Biol Chem 274 : 34967 34973.
37. Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, Monkkonen J et al. (1999). Molecular mechanisms of action of bisphosphonates. Bone 24 : 73S 79S.
38. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J et al. (2000). Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88 : 2961 2978.
39. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA et al. (2006). Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81 : 1013 1022.
40. Soderling TR, Stull JT (2001). Structure and regulation of calcium/calmodulin-dependent protein kinases. Chem Rev 101 : 2341 2352.
41. Sudo H, Kodama HA, Amagai Y, Yamamoto S, Kasai S (1983). In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria. J Cell Biol 96 : 191 198.
42. Suzuki A, Ghayor C, Guicheux J, Magne D, Quillard S, Kakita A et al. (2006). Enhanced expression of the inorganic phosphate transporter Pit-1 is involved in BMP-2-induced matrix mineralization in osteoblast-like cells. J Bone Miner Res 21 : 674 683.
43. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H et al. (2002). Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3 : 889 901.
44. Vinatier C, Magne D, Weiss P, Trojani C, Rochet N, Carle GF et al. (2005). A silanized hydroxypropyl methylcellulose hydrogel for the three-dimensional culture of chondrocytes. Biomaterials 26 : 6643 6651.
45. Warrell RP, Jr., Bockman RS, Coonley CJ, Isaacs M, Staszewski H (1984). Gallium nitrate inhibits calcium resorption from bone and is effective treatment for cancer-related hypercalcemia. J Clin Invest 73 : 1487 1490.
46. Warrell RP, Jr., Skelos A, Alcock NW, Bockman RS (1986). Gallium nitrate for acute treatment of cancer-related hypercalcemia: clinicopharmacological and dose-response analysis. Cancer Res 46 : 4208 4212.
47. Warrell RP, Jr., Israel R, Frisone M, Snyder T, Gaynor JJ, Bockman RS (1988). Gallium nitrate for acute treatment of cancer-related hypercalcemia. A randomized, double-blind comparison with calcitonin. Ann Intern Med 108 : 669 674.
48. Warrell RP, Jr., Bosco B, Weinerman S, Levine B, Lane J, Bockman RS (1990). Gallium nitrate for advanced Paget disease of bone: effectiveness and dose-response analysis. Ann Intern Med 113 : 847 851.
49. Wittrant Y, Theoleyre S, Couillaud S, Dunstan C, Heymann D, Redini F (2004). Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kB ligand and osteoprotegerin biological activities. Exp Cell Res 293 : 292 301.